Natera, Inc. Common Stock (NTRA) is a publicly traded Healthcare sector company. As of May 20, 2026, NTRA trades at $205.88 with a market cap of $27.57B and a P/E ratio of -124.56. NTRA moved +4.51% today. Year to date, NTRA is -13.69%; over the trailing twelve months it is +32.61%. Its 52-week range spans $117.27 to $256.36. Analyst consensus is strong buy with an average price target of $262.14. Rallies surfaces NTRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Natera Q1 Revenues Surge 38.8% to $696.6 Million with 64.7% Margin: Natera reported Q1 2026 revenues of $696.6 million, a 38.8% increase from $501.8 million in Q1 2025, driven by higher test volumes. Gross margin improved to 64.7% from 63.1%, reflecting enhanced operational efficiencies.
| Metric | Value |
|---|---|
| Price | $205.88 |
| Market Cap | $27.57B |
| P/E Ratio | -124.56 |
| EPS | $-1.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $256.36 |
| 52-Week Low | $117.27 |
| Volume | 1.33M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.50B |
| Net Income | $-226.31M |
| Gross Margin | 0.00% |
16 analysts cover NTRA: 0 strong buy, 15 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $262.14.